Basis for Immunotherapy for Treatment of Meningiomas

A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours

(2020) Claire L. Adams et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The prognostic role of Ki-67/MIB-1 in meningioma

(2020) Ning Liu et al.   MEDICINE

Rapid development of an atypical meningioma during Nivolumab therapy for metastatic renal cell carcinoma

(2020) N. Abele et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Systemic and local immunosuppression in patients with high-grade meningiomas

(2019) Yuping D. Li et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Multimodality Therapy of Patients with Refractory Meningiomas

(2019) Haroon Ahmad et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

(2019) Carlo Capalbo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).

(2019) Matthias Preusser et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas

(2019) Shuyu Hao et al.   JOURNAL OF NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

(2019) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors

(2019) Akash J. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma

(2019) Jiaojiao Deng et al.   World Neurosurgery

Current Role of Radiation Therapy in the Management of Malignant Central Nervous System Tumors

(2019) Ahsan Farooqi et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence

(2018) Leah M. Katz et al.   ACTA NEUROPATHOLOGICA

Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors

(2018) Shiyang Wang et al.   JOURNAL OF NEURO-ONCOLOGY

Integrated genomic analyses of de novo pathways underlying atypical meningiomas

(2018) Akdes Serin Harmancı et al.   Nature Communications

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

(2018) Remy Thomas et al.   Frontiers in Immunology

Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma

(2018) Laura Pinton et al.   OncoImmunology

OUP accepted manuscript

(2018)   NEURO-ONCOLOGY

Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma

(2018) Dustin Proctor et al.   OncoImmunology

Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?

(2018) Constantin A Dasanu et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

New molecular targets in meningiomas

(2018) Vyshak Alva Venur et al.   CURRENT OPINION IN NEUROLOGY

Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges

(2017) Etienne Giroux Leprieur et al.   EUROPEAN JOURNAL OF CANCER

Innate immunity may play a role in growth and relapse of chordoid meningioma

(2017) Ivan Presta et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature

(2017) Efrat Gelerstein et al.   JOURNAL OF CLINICAL NEUROSCIENCE

The use of immunotherapy in the treatment of melanoma

(2017) Tala Achkar et al.   Journal of Hematology & Oncology

Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?

(2017) Pedro Góes et al.   JOURNAL OF NEURO-ONCOLOGY

Atypical and anaplastic meningioma: outcomes in a population based study

(2017) T. Garzon-Muvdi et al.   JOURNAL OF NEURO-ONCOLOGY

Meningioma recurrence rates following treatment: a systematic analysis

(2017) Victor Lam Shin Cheung et al.   JOURNAL OF NEURO-ONCOLOGY

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis

(2017) Felix Sahm et al.   LANCET ONCOLOGY

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet

(2017) Anna C. Filley et al.   Oncotarget

PD1 signal transduction pathways in T cells

(2017) Hugo Arasanz et al.   Oncotarget

Checkpoint inhibition: new treatment options in urologic cancer

(2017) Daan Joost De Maeseneer et al.   ACTA CLINICA BELGICA

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

(2017) Aaron M. Goodman et al.   OncoImmunology

Immunotherapy Progress in Mismatch Repair–Deficient Colorectal Cancer and Future Therapeutic Challenges

(2016) James T. Link et al.   CANCER JOURNAL

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma

(2016) Seunggu J. Han et al.   JOURNAL OF NEURO-ONCOLOGY

Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes

(2016) Ariel E. Marciscano et al.   JOURNAL OF NEUROSURGERY

The Simpson grading revisited: aggressive surgery and its place in modern meningioma management

(2016) Konstantinos Gousias et al.   JOURNAL OF NEUROSURGERY

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges

(2016) Baofeng Wang et al.   MOLECULAR CARCINOGENESIS

Spinal meningiomas: clinicoradiological factors predicting recurrence and functional outcome

(2016) Tanmoy K. Maiti et al.   Neurosurgical Focus

Advances in targeted and immunobased therapies for colorectal cancer in the genomic era

(2016) Heng Seow et al.   OncoTargets and Therapy

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review

(2015) Leland Rogers et al.   JOURNAL OF NEUROSURGERY

Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States

(2015) Varun R. Kshettry et al.   NEURO-ONCOLOGY

An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas

(2015) Sam Q. Sun et al.   Neurosurgical Focus

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma

(2015) Ziming Du et al.   Oncotarget

Tumor-intrinsic oncogene pathways mediating immune avoidance

(2015) Stefani Spranger et al.   OncoImmunology

Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma

(2014) Adriana Olar et al.   BRAIN PATHOLOGY

Biochemical Signaling of PD-1 on T Cells and Its Functional Implications

(2014) Vassiliki A. Boussiotis et al.   CANCER JOURNAL

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas

(2014) Jeffrey J. Raizer et al.   JOURNAL OF NEURO-ONCOLOGY

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review

(2014) T. Kaley et al.   NEURO-ONCOLOGY

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

(2014) Thomas J. Kaley et al.   NEURO-ONCOLOGY

Management of Atypical Cranial Meningiomas, Part 2

(2014) Sam Q. Sun et al.   NEUROSURGERY

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

(2013) Jérôme Galon et al.   IMMUNITY

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

(2013) Priscilla K Brastianos et al.   NATURE GENETICS

The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells

(2013) L. Fang et al.   NEURO-ONCOLOGY

Association between Inflammatory Infiltrates and Isolated Monosomy 22/del(22q) in Meningiomas

(2013) Patrícia Henriques Domingues et al.   PLoS One

Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO

(2013) V. E. Clark et al.   SCIENCE

NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches

(2013) G. S. Baia et al.   Cancer Immunology Research

Radiation Treatment for WHO Grade II and III Meningiomas

(2013) Brian P. Walcott et al.   Frontiers in Oncology

Immunophenotypic Identification and Characterization of Tumor Cells and Infiltrating Cell Populations in Meningiomas

(2012) Patrícia H. Domingues et al.   AMERICAN JOURNAL OF PATHOLOGY

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

(2011) M J M Gooden et al.   BRITISH JOURNAL OF CANCER

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

(2011) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Epidemiology and etiology of meningioma

(2010) Joseph Wiemels et al.   JOURNAL OF NEURO-ONCOLOGY

Medical therapies for meningiomas

(2010) Patrick Y. Wen et al.   JOURNAL OF NEURO-ONCOLOGY

Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas

(2010) Michael E. Sughrue et al.   JOURNAL OF NEUROSURGERY

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

(2009) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)

(2009) Patrick Y. Wen et al.   NEURO-ONCOLOGY

LONG-TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION

(2009) Manish K. Aghi et al.   NEUROSURGERY

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions

(2008) M. Ahmadzadeh et al.   BLOOD

Meningioma

(2008) Christine Marosi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The microglial/macrophagic response at the tumour-brain border of invasive meningiomas

(2008) S. Grund et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY